Autosomal recessive ataxia due to ubiquinone deficiency

Autosomal recessive ataxia due to ubiquinone deficiency, also known as autosomal recessive cerebellar ataxia due to coenzyme Q10 deficiency, is a rare inherited neurological disorder characterized by progressive cerebellar ataxia resulting from a deficiency of coenzyme Q10 (ubiquinone) in muscle tissue and other cells. Coenzyme Q10 is a critical component of the mitochondrial electron transport chain, essential for cellular energy production. When deficient, tissues with high energy demands — particularly the brain and muscles — are disproportionately affected. The condition primarily affects the nervous system, especially the cerebellum, leading to progressive difficulty with coordination and balance (cerebellar ataxia). Patients typically present in childhood or adolescence with gait ataxia, limb incoordination, dysarthria (slurred speech), and sometimes seizures. Additional features may include exercise intolerance, muscle weakness, and cerebellar atrophy visible on brain imaging. Some patients may also develop intellectual disability, pyramidal signs, or peripheral neuropathy. The severity and age of onset can vary depending on the specific genetic cause and degree of ubiquinone deficiency. This condition is caused by mutations in genes involved in the biosynthesis of coenzyme Q10, including APTX (aprataxin), ADCK3/COQ8A, and other COQ-pathway genes. Importantly, this is one of the few inherited ataxias for which a specific treatment exists: oral supplementation with coenzyme Q10 (ubiquinone) has been shown to stabilize or improve neurological symptoms in some patients, particularly when initiated early in the disease course. High-dose CoQ10 supplementation is the mainstay of therapy, though response varies among individuals. Early diagnosis is therefore critical to optimize treatment outcomes.

Common questions about Autosomal recessive ataxia due to ubiquinone deficiency